Minneapolis, MN – According to filings with the U.S. Securities and Exchange Commission, DiaMedica Therapeutics is raising $29,999,995.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Rick Pauls played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

To learn more about DiaMedica Therapeutics, visit http://www.diamedica.com/

Contact:
Rick Pauls, Chief Executive Officer
763-312-6755
rpauls@diamedica.com
https://www.linkedin.com/in/rick-pauls-33b8a63/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved